EMA exempts labeling rules during shortages; Xellia hiring at new U.S. plant;

> The EMA in new guidance explains how in the case of some shortages drugmakers can sell products that do not follow EU labeling and packaging rules. Report

> The European Medicine Agency (EMA) has received two dozen comments on its guidance for declaring that good manufacturing practices (GMP) have been followed by a company. Report

> Xellia Pharmaceuticals said it is hiring at the plant it recently acquired from Fresenius Kabi, a deal supported by incentives from various North Carolina jurisdictions. Release

> A new report says China has established a relatively comprehensive pharmacovigilance system. Abstract